** Drugmaker BioMarin Pharmaceutical's BMRN.O shares rise ~1.8% to $68.25 premarket
** Oppenheimer upgrades BMRN to "outperform" from "perform" rating
** Brokerage says new management's focus on operational efficiencies, cost reduction and return on R&D investments will boost BMRN's revenue growth
** Twenty-three of 29 brokerages rate the stock "buy" or higher, 6 "hold"; their median PT is $95 - data compiled by LSEG
** As of last close, stock up ~3.8% YTD
(Reporting by Prakhar Srivastava in Bengaluru)
((Prakhar.srivastava2@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.